PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 19, 2026Clinical Cancer Research0 citations

Piggybacking Towards Progress for CAR-T Cell Therapy in Prostate Cancer

View Full Paper
PLPatrick C. LeeMSMichael T. SchweizerRNRosa Nadal

Key Points

  • This research aims to evaluate the clinical effectiveness and safety of P-PSMA-101 CAR-T cell therapy in treating prostate cancer.
  • First-in-class CAR-T therapy targeting PSMA was administered to patients.
  • Focused on stem cell memory T cell-enriched populations for treatment efficacy.
  • Utilization of a novel iCasp9 safety switch to manage toxicity.
  • Two patients demonstrated notable clinical activity with the therapy.
  • PSA50 responses varied, showing generally modest results.
  • Severe toxicities occurred but were effectively mitigated by the iCasp9 safety switch.

Abstract

P-PSMA-101 is a first-in-class, stem cell memory T cell-enriched, PSMA-targeting CAR-T therapy. This cellular therapy showed notable clinical activity in two patients; however, PSA50 responses were generally modest. While severe immune effector-related toxicities were observed in some patients, a novel iCasp9 safety switch was largely effective in mitigating toxicity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Lee et al. (2026) studied this question.

synapsesocial.com/papers/6a34df7565a5b0777af2e8c8https://doi.org/10.1158/1078-0432.ccr-26-0959
Ask AI
Helpful
Bookmark
Share
View Full Paper